GeoVax Labs (NASDAQ:GOVX) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research note published on Tuesday morning, Benzinga reports. They currently have a $8.00 price objective on the stock.

GeoVax Labs Stock Down 12.4 %

Shares of NASDAQ:GOVX opened at $2.90 on Tuesday. The business’s 50 day moving average price is $1.88 and its 200-day moving average price is $2.69. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $10.24.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($2.47) earnings per share for the quarter. As a group, equities research analysts anticipate that GeoVax Labs will post -7.41 EPS for the current year.

Hedge Funds Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC bought a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned approximately 91.38% of GeoVax Labs at the end of the most recent quarter. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.